TMC-256C1

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameTMC-256C1
Drug Alias NamefonsecinIL-4 Inhibitors (Tanabe)TMC-256C1TMC-256B1
ClassificationNatural product/ExtractSmall molecules
Mechanisms of ActionInterleukin-4 receptors inhibitorsInterferon gamma receptor antagonists
TargetsInterleukin-4 receptorsInterferon gamma receptor
Therapy Area/IndicationsHypersensitivityBacterial Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesTanabe Seiyaku Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTanabe Seiyaku Co Ltd
Active IndicationsN/A
Inactive IndicationsHypersensitivityBacterial Infections

Other Information

ATC CodeN/A
Related LinksN/A